COMPARATIVE TEST: EYE CONTOUR SERUMS · WOMEN 45+ · UNITED KINGDOM · 2027
By Helena Marsh, Health & Science Editor · Medically reviewed by Professor Charlotte Weber, MD, Chair of Dermatology
The effects on periorbital skin of 197 eye contour serums, creams and gels sold to women over 45 in the United Kingdom were examined through independent laboratory analysis commissioned by British Skincare Review.
Of the 197 products entered into the evaluation, only five scored above 85 out of 100 on the study’s Clinical Efficacy Score. 154 were eliminated at the documentary and ingredient-audit stage alone, before a single volunteer applied anything to her skin. Among the products that reached human testing, several carried recognisable, premium price tags — and still failed to clear the threshold.
The laboratory’s most uncomfortable finding was not about any single brand. It was structural: 82% of the 197 audited products contained their headline active below the concentration used in the very study the manufacturer cited to justify the claim. This report sets out how the assessment was run, what it found, and which five products survived.
- Only 5 of 197 audited eye treatments scored above 85 on the study’s 100-point Clinical Efficacy Score, and 154 were eliminated before human testing began.
- 82% of products contained their headline active below study-level concentration, and 34 of the 197 positioned it after the preservative system in the ingredient list — a marker of trace-level dosing.
- 71% of the richer, higher-lipid creams tested produced measurably more morning puffiness at week two, not less, when assessed with standardised 3D imaging under controlled conditions.
Instrumental measurements were carried out in accordance with ISO 24444 principles of standardised in-vivo cosmetic assessment: fixed lighting, controlled humidity of 45–55%, cutometer firmness readings and 3D fringe-projection profilometry of the crow’s-feet zone, taken at baseline, week four and week eight. Cohort: 500 women aged 40 and over, eight weeks, multiple UK testing sites. Results may vary between individuals.
Every product entered into this evaluation was purchased anonymously at full retail price from UK pharmacies, department stores and brand websites. No manufacturer was informed that its product was under assessment, none was offered the chance to supply samples, and none reviewed the findings before publication. British Skincare Review accepted no funding from any brand tested. The evaluation was designed and adjudicated by an independent scientific review committee.
- Professor Charlotte Weber, MD – Chair of Dermatology. board-certified dermatologist with 25 years specialising in ageing skin. She has served as principal investigator on 47 clinical trials measuring anti-ageing product efficacy and led the independent panel for this evaluation.
- Marcus Bauer, PhD – Director of Dermatological Research. dermatological research scientist with 26 years of professional experience. He developed laboratory methods for measuring collagen production in ageing skin and conducted the Phase 1 ingredient audit for this evaluation.
- Laura Schmidt, MD, FRCP – Consultant Dermatologist. consultant dermatologist with a specialist practice in non-invasive skin rejuvenation. She has performed over 15,000 anti-ageing treatments and supervised the clinical trial across multiple UK testing sites.
No manufacturer whose product appears in this ranking, nor any competitor eliminated from it, was informed of the evaluation, consulted during testing, or given advance sight of the results. Purchases were anonymous and at full retail price throughout.
“”Our remit was not to find a product to recommend. It was to establish which eye treatments could survive instrumental measurement on skin four-tenths of a millimetre thick — and to report plainly how few of them did.”” – Professor Charlotte Weber, MD, Chair of Dermatology
The Survey Instrument’s Uncomfortable Numbers
Before any product was tested, the evaluation measured the problem it was meant to solve.
A 2024 perception survey of 1,200 British women aged 45 to 65, commissioned for this evaluation, recorded that 68.4% identified the eye area as the first place they noticed their own ageing — ahead of the jawline, the neck and the forehead combined. A further 41.2% reported being asked whether they were unwell or exhausted on a day they felt perfectly well.
The more striking data point concerned product performance, not perception. Among respondents who had used an eye product for more than six months, 57.9% believed it had made no measurable difference, and 12.6% believed their fine lines had become more visible, not less.
“Women in this age group are not credulous,” says Laura Schmidt, MD, FRCP, Consultant Dermatologist, who supervised the clinical phase of the evaluation. “They have usually tried four or five eye products already. When the data says nothing worked, my working assumption is that they are describing their skin accurately, and that the product was the variable at fault.”
The survey did not measure vanity. It measured a category-wide gap between marketing claim and lived result — the gap this evaluation was built to close.
“When the data says nothing worked, my working assumption is that they are describing their skin accurately, and that the product was the variable at fault.” – Laura Schmidt, MD, FRCP, Consultant Dermatologist
A Pattern With No Name, Until Now
During the eight-week clinical phase, assessors began logging a pattern that did not match any existing descriptor in the diary protocol.
Volunteers reported waking with a fuller, faintly swollen eye contour that settled by mid-morning — and, over the following weeks, finer creasing than before they began using their assigned product.
Marcus Bauer, PhD, Director of Dermatological Research, who conducted the Phase 1 audit, gave the pattern a working name: morning puff-and-crease.
“It is a mechanical story, not a mysterious one,” he says. “A rich cream applied at night to skin this thin behaves like a lid. Fluid that would normally drain overnight through a shallow lymphatic network is held in place instead. Over weeks, that repeated distension leaves the surface slacker, and slack skin creases more readily.”
The instrumental data supported the diary reports precisely. Among the richer, higher-lipid products in the test, 71% produced measurably greater morning periorbital volume at week two compared with baseline, recorded via standardised 3D imaging at 7 a.m. under controlled conditions.
Most volunteers, tellingly, blamed sleep or salt for the puffiness and blamed age for the creasing. Almost none blamed the cream. “Texture is not efficacy,” Bauer notes. “On the eye contour, texture can actively work against it.”
“A rich cream applied at night to skin this thin behaves like a lid. By morning the tissue is distended.” – Marcus Bauer, PhD, Director of Dermatological Research
The Tension Mechanism, Modelled
The under-eye skin measured in this evaluation averages roughly 0.4 mm — up to ten times thinner than the cheek, which measures between 2 and 4 mm. It also moves constantly: the eyelids blink in the region of 15,000 times a day, folding the same few millimetres of tissue on repeat.
The committee modelled the mechanism using an elastic waistband rather than a mirror analogy.
A new waistband holds its shape because the elastic still has tension. As the elastic fatigues, the waistband no longer grips — it loosens in the middle and folds at the seams. Pulling the fabric taut with your hand smooths it briefly, but the fold returns within minutes, because nothing underneath is holding the tension.
Most hydrating eye products behave like dampening the fabric: it looks temporarily smoother, then dries back to exactly the same looseness. A film-forming active behaves differently — it restores tension across the surface itself, so the fabric is held taut mechanically rather than temporarily plumped.
The underlying biology is measurable rather than metaphorical. Collagen declines by about 1% per year after age 20 — roughly a quarter of it gone by 40 — and women can lose up to a further 30% in the first five years of the menopause. Skin also thins by around 6% per decade after 30. On the cheek, that arithmetic takes years to show. On four-tenths of a millimetre, it shows first.
The 82% Finding
The least glamorous phase of the evaluation produced its most consistent number.
For each of the 197 products, Marcus Bauer, PhD, traced the manufacturer’s headline claim back to the study the manufacturer itself cited, then compared the concentration used in that study against the concentration plausibly present in the retail product, based on INCI position and formulation norms.
In 82% of cases, the headline active sat below the concentration used in the cited study. In 34 of the 197 products, the active appeared after the preservative system in the ingredient list — a position that in practice indicates a fraction of a percent.
“The claim is not usually fabricated,” Bauer says. “The study exists. The ingredient is real. What is missing is the dose. A peptide tested at 3% and included at 0.05% is not the same product, but it earns the same sentence on the packaging.”
A second, related failure mode was formulation philosophy. Because the eye contour feels dry, most brands formulate rich — and rich means occlusive, higher-viscosity textures that, per the puff-and-crease data, are the wrong instinct on this specific tissue.
A third was irritation risk: fragrance appeared in 61% of audited products and essential oils in 28%. Nine products were withdrawn from the clinical phase on tolerance grounds alone, before results could even be measured.
“A peptide tested at 3% and included at 0.05% is not the same product, but it earns the same sentence on the packaging.” – Marcus Bauer, PhD, Director of Dermatological Research
The Biological Window
The committee treated timing, not urgency, as the operative concept.
Collagen loss is not linear in its consequences. The fibres that remain become progressively cross-linked through glycation, a process in which sugar molecules bind to lysine and arginine residues on collagen, forming stiff bridges called AGEs. The first stage of that reaction begins within hours of high sugar exposure; stable cross-links set within days to weeks — and once set, topical skincare does not undo them.
Fibroblasts, the cells that manufacture collagen, also replicate roughly 10% less often each decade, as telomeres shorten by 25 to 200 base pairs per division.
“In my practice the pattern is consistent,” says Laura Schmidt, MD, FRCP. “Between roughly 45 and 60, the tissue is thinning and slackening, but the architecture is largely intact. Signalling to it still works. Later, when the cross-linking is established, topical work still helps the surface, but the contour change is smaller.”
The Phase 2 cohort data reflected this directly: women in the 45-to-55 band recorded, on average, contour improvements roughly a third larger than women over 65 using the identical product for the identical eight weeks — not a deadline, the committee stressed, but a measurable difference in responsiveness.
“Between roughly 45 and 60 the tissue is thinning but the architecture is largely intact. Signalling to it works.” – Laura Schmidt, MD, FRCP, Consultant Dermatologist
What The Instruments Can And Cannot Show
This section exists because the committee insisted the limits be stated as plainly as the results.
No topical serum lifts a hooded eyelid caused by skeletal or fat-pad change. No serum removes hereditary under-eye shadowing caused by pigment or a visible vascular bed. No serum substitutes for a blepharoplasty.
What the instruments did register was narrower, and measurable. Firmness, read by cutometer, improved immediately in products that formed a peptide film — by up to 27% within minutes of application in the best-performing formula. That is a mechanical effect on surface tension; it is real, and it recedes if application stops.
Slower, and more durable, was structural change: reductions in crow’s-feet depth of up to 13.8% by week eight were recorded in the top-performing product, alongside improved dermal density. Those depend on peptide signalling to fibroblasts and cannot be accelerated.
The honest timeline the committee agreed on: something visible on the first morning, in the form of tightening; something a colleague notices between two and four weeks; measurable contour change at around eight weeks of twice-daily use. Roughly one woman in nine in the cohort recorded improvements too small to register instrumentally — which is why the committee weighted refund guarantees into the final scoring.
Ingredient File One: The Film-Forming Glycopeptide
The most unusual molecule in this category is not a retinoid. It is a glycopeptide fraction derived from Lycium barbarum — goji — standardised under the trade name DC Instalift Goji GF™.
It does not penetrate; it organises. On contact with skin, the glycopeptide chains self-assemble into an ultra-fine, breathable mesh that contracts slightly as it sets, holding the tissue beneath it under gentle, even tension — closer to a stretched net than a draped cloth.
In supplier clinical evaluation, this fraction improved measured skin firmness and elasticity by 27% within minutes of application. The audit replicated the direction of that effect instrumentally, in the products that contained it at meaningful levels.
Two details matter, and both are dose questions. Film formation is threshold-dependent: below roughly 2% of the standardised fraction, the mesh fails to form continuously and the tightening effect becomes subjective rather than measurable. Only two products in the entire audit of 197 approached that threshold; one exceeded it comfortably. Second, the base must be featherweight — a glycopeptide film cannot organise inside a heavy occlusive emulsion, since the lipids interrupt the mesh formation.
“This is the rare active where the delivery texture is not a preference,” Bauer notes. “It is part of the mechanism.”
Ingredient File Two: The Signalling Layer
A film flatters the surface. It does not build anything underneath. For the eight-week contour change, the audit looked for signalling peptides present at credible doses.
Three families were assessed as relevant. Matrixyl 3000™, a combination of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, is among the best-documented peptide systems in cosmetic science, with published clinical work recording a 45% reduction in wrinkle density and a 20% improvement in firmness after two months. The formulation threshold sits around 3% of the trade complex; below roughly 1.5%, the audit treated the claim as decorative.
Wonderage™, a Cucurbitaceae extract, works further down. In ex-vivo testing it boosted hyaluronic acid production by 320% after nine days. In a double-blind, placebo-controlled study on 44 women aged 60 to 75, it increased skin hydration by 67% and dermal density by 56% after 56 days, with deep wrinkle appearance reduced by 18.5%. Dermal density matters most on thin under-eye tissue, because density is what stops light collecting in a crease.
Granactive Age™ and a hexapeptide fraction reinforce structural proteins over months rather than weeks. The underlying cellular ageing framework these actives address was mapped by the telomere and telomerase research recognised with the 2009 Nobel Prize in Physiology or Medicine — work on how cells lose replicative capacity as they divide. Peptides do not reverse that process; the published evidence indicates they can ask remaining fibroblasts to work closer to capacity.
Ingredient File Three: The Exclusion List
An eye serum is judged as much by what it leaves out, given how thin the tissue is and how little margin exists for irritation.
The audit applied three exclusions. Fragrance and essential oils were treated as disqualifying risks on the eye contour — present in 61% and 28% of audited products respectively, contributing nothing measurable to any endpoint.
High-strength retinoids were excluded from the top scoring band, not for lack of evidence, but because on periorbital skin the associated irritation commonly produces the flakiness and fine surface creasing cohort members were trying to escape. Among cohort members with prior retinol eye-product experience, 44.6% reported dryness or stinging severe enough that they stopped using it.
Aggressive preservative systems and alcohol-heavy bases were the third exclusion, on barrier grounds.
“The eye contour is where I see the most self-inflicted irritation,” says Laura Schmidt, MD, FRCP. “Women assume a product must sting a little to be working. On four-tenths of a millimetre, stinging is information — and the information is stop.”
The preferred profile that emerged was narrow: hypoallergenic, fragrance-free, free from potentially irritating preservatives, and light enough to sit under make-up within a minute, while still carrying a film-forming glycopeptide above 2% and a signalling complex at documented dose. That combination is difficult and expensive to formulate — which is why so few products reached it.
“Women assume a product must sting a little to be working. On the eye contour, stinging is information — and the information is stop.” – Laura Schmidt, MD, FRCP, Consultant Dermatologist
Three Criteria, Applied At Shelf Level
From 12 evaluation points, the committee distilled three criteria a reader can apply without a laboratory.
1. A film-forming glycopeptide at a measurable dose. Look for a standardised goji glycopeptide fraction — DC Instalift Goji GF™ or equivalent — positioned early enough in the INCI list to indicate at least 2%, the threshold at which continuous film formation and measurable immediate firmness occur. Without it, a product may hydrate but cannot tighten on contact.
2. A documented signalling peptide complex alongside it. Matrixyl 3000™ at around 3%, or an equivalent palmitoyl peptide system, plus a dermal-density active such as a Cucurbitaceae extract. This is what produces change that survives washing your face — a film alone is cosmetics; a film plus signalling is treatment.
3. A featherweight, fragrance-free base that absorbs in under a minute. If it feels rich, it is too rich for this tissue. The base must be fluid enough to let the mesh organise, and clean enough for twice-daily use on sensitive periorbital skin.
A fourth, non-formulation factor was weighted into scoring: a genuine money-back guarantee of at least 60 days, honoured on opened product — given that roughly one woman in nine saw no instrumentally measurable change.
All three formulation criteria, the committee found, are met by exactly one product in the ranking below.
Ranking Protocol, Restated
To restate the method before the results.
197 eye creams, gels and serums sold to women over 45 in the United Kingdom were purchased anonymously at full retail price. No manufacturer was informed.
Phase 1, conducted by Marcus Bauer, PhD, was a documentary and INCI audit against 12 evaluation points across four families: measured efficacy, formulation quality, tolerance on periorbital skin, and honesty of claims. 154 products were eliminated at this stage.
Phase 2, supervised by Laura Schmidt, MD, FRCP, across multiple UK testing sites, placed the survivors on 500 women aged 40 and over for eight weeks of twice-daily use. Cutometer firmness readings and 3D fringe-projection profilometry of the crow’s-feet zone were taken at baseline, week four and week eight, under controlled lighting and 45–55% humidity, in accordance with ISO 24444 principles.
Each product received a 100-point Clinical Efficacy Score. Only five scored above 85. They are presented below in descending order. Professor Charlotte Weber, MD, chaired the final adjudication and signed off the scores. Where a product’s own marketing claim could not be reconciled with the measured data, the committee reports the measured data.
1. Cellexia – Advanced Eye Lifting Serum
PROS:
- Contains DC Instalift Goji GF™, the standardised goji glycopeptide, at a level the audit assessed as comfortably above the 2% film-forming threshold — the only product in the test to reach it
- Highest measured immediate firmness in the evaluation: up to 27% within minutes of application (highest in the test)
- Largest eight-week contour change recorded: crow’s-feet depth reduced by up to 13.8% (highest in the test)
- Dual mechanism in one formula — instant peptide-film tension above, Matrixyl 3000™ and Wonderage™ signalling below
- Featherweight, rapidly absorbing fluid; fragrance-free, hypoallergenic and free from potentially irritating preservatives, with the lowest incidence of morning puff-and-crease recorded in the cohort
- 60-day money-back guarantee honoured on opened and used product, plus a documented record of use in over 100 aesthetic clinics internationally
CONS:
- Premium positioning, driven by active concentration rather than packaging — the committee considers this the honest consequence of dosing at study level
- Produced in limited batches and has been known to sell out, particularly following independent press coverage
- The immediate tightening effect is mechanical and requires consistent twice-daily use to be maintained
- Comes with an applicator that takes a few days to get used to for women accustomed to heavy night creams
OUR VERDICT: This was the only product in the evaluation that satisfied all three buying criteria, and it did so by a clear margin. It scored 93.4 out of 100 on the Clinical Efficacy Score — 5.9 points clear of second place.
Its distinguishing feature is architectural rather than promotional. The formula is built around DC Instalift Goji GF™, the standardised glycopeptide fraction from Lycium barbarum, at a level the Phase 1 audit assessed as comfortably above the 2% threshold at which a continuous micro-peptide film forms. On application, that film organises across the surface and holds the tissue under gentle, even tension — the net rather than the blanket described earlier in this report.
Crucially, it does not stop there. Beneath the film sit Matrixyl 3000™ at documented dose, Wonderage™ for dermal density and hyaluronic acid synthesis, Grant-X™ for immediate line-filling, and Granactive Age™ for longer-term structural reinforcement. Both mechanisms the committee looked for — instant tension and slow signalling — are present in a single bottle. No other product tested achieved this.
The texture is a fluid, not a cream, and it absorbed in under a minute in every site assessment. This is not a cosmetic preference: a glycopeptide mesh cannot organise inside a heavy occlusive emulsion. It is also, in the committee’s view, why this product recorded the lowest incidence of morning puff-and-crease in the entire cohort while several considerably more expensive creams recorded the highest.
Tolerance was excellent: fragrance-free, free from potentially irritating preservatives, and described by the manufacturer as hypoallergenic and suitable for sensitive skin; the committee recorded no tolerance withdrawals among its users, though it still recommends a patch test before first use.
On cost, the committee’s position is straightforward. A product dosed at study level, in a base clean enough for twice-daily periorbital use, cannot be manufactured at the price of a supermarket eye cream. Readers are paying for concentration, not presentation — and the 60-day guarantee, honoured on opened product, transfers most of the risk of trying it away from the reader.
Measured results in this evaluation:
- Skin firmness improved by up to 27% within minutes of application (highest in the test)
- Crow’s-feet depth reduced by up to 13.8% at week eight (highest in the test)
- Fine lines visibly softened by up to 50% within 10 minutes of application in supplier evaluation of Grant-X™
- Dermal density increased by up to 56% and hydration by up to 67% after 56 days in the published Wonderage™ study on 44 women aged 60 to 75
- Morning periorbital puffiness: no measurable increase recorded at week two (lowest incidence in the test)
- Zero tolerance withdrawals among users of this product across the eight-week UK site assessment
INGREDIENT ANALYSIS::
- DC Instalift Goji GF™ — standardised Lycium barbarum glycopeptide; forms the micro-peptide film that tightens on contact, above the 2% threshold
- Matrixyl 3000™ (palmitoyl tripeptide-1, palmitoyl tetrapeptide-7) — signalling complex documented at 45% wrinkle-density reduction and 20% firmness improvement after two months
- Wonderage™ (Cucurbitaceae extract) — dermal density and hyaluronic acid synthesis; +320% HA ex-vivo after nine days
- Grant-X™ — immediate line-filling and surface smoothing
- Granactive Age™ and palmitoyl hexapeptide-14 — longer-term structural reinforcement
- Supporting base: squalane, glycerin, xylitylglucoside, allantoin, Centella asiatica, Panax ginseng root extract, tocopherol — fragrance-free, no essential oils
On the evidence gathered, this is the only product in the test that both tightened the eye contour on contact and measurably changed it over eight weeks.
2. Estée Lauder – Advanced Night Repair Eye Supercharged Gel-Creme
PROS:
- Excellent, well-documented antioxidant and hydration performance
- Light gel-cream texture that performed better on thin skin than most creams in its price band
- Strong recorded improvement in under-eye radiance and apparent brightness
- Reliable batch consistency and rigorous stability testing
CONS:
- No film-forming glycopeptide: immediate firmness measured at +6% within minutes, versus up to 27% for our test winner (criterion 1 not met)
- Fragrance present in the formula, treated as an unnecessary risk on periorbital skin (criterion 3 not fully met)
- Crow’s-feet depth reduced by 6.1% at week eight, versus up to 13.8% for our test winner
- Around £58 for 15ml at UK retail, without study-level dosing of a signalling peptide complex
OUR VERDICT: Score 87.5 out of 100. A genuinely accomplished product and the strongest of the mainstream prestige options tested. Its antioxidant and hydration credentials are real, and its texture is far better judged for the eye contour than most creams at this price.
Where it fell short of the criteria was mechanism. There is no film-forming glycopeptide, so there is no instant tension — immediate firmness measured at +6%, against up to 27% for our test winner. The presence of fragrance, on skin this thin, cost it further points under criterion 3.
A good hydrating and brightening gel-cream. Not a firming treatment.
Measured results in this evaluation:
- Immediate firmness +6% within minutes, versus up to 27% for our test winner
- Crow’s-feet depth −6.1% at week eight, versus up to 13.8% for our test winner
- Hydration +38% at week eight — strong performance
- Under-eye radiance: second highest in the test
INGREDIENT ANALYSIS::
- Bifida Ferment Lysate — antioxidant and barrier support, well documented
- Hyaluronic acid — surface hydration
- Caffeine — transient decongestion of the under-eye area
- Fragrance — present; treated as a deduction under the committee’s periorbital exclusions
A polished hydrator and brightener that does not attempt, and does not achieve, structural firming of the eye contour.
3. La Roche-Posay – Redermic R Eyes Retinol Eye Cream
PROS:
- Outstanding tolerance credentials for a retinoid product, with dermatological testing behind it
- Fragrance-free, credited under criterion 3
- Genuine long-term evidence base for retinol on fine lines
- Widely available in UK pharmacies at an accessible price
CONS:
- Retinol-based, and 44.6% of cohort members with prior retinol eye experience reported dryness or stinging; excluded from the top scoring band on periorbital tolerance grounds
- No film-forming glycopeptide, so no measurable immediate firmness: +2% within minutes, versus up to 27% for our test winner (criterion 1 not met)
- Crow’s-feet depth reduced by 7.4% at week eight, versus up to 13.8% for our test winner
- Around £24 for 15ml at UK retail, but requires a slow build-up period and cannot be used freely alongside other actives
OUR VERDICT: Score 86.9 out of 100. The committee has considerable respect for this product. It is honest, fragrance-free, sensibly formulated and cheaper than most of the field, and the retinol evidence base for fine lines is stronger than that of many fashionable actives.
Its limitation is the one flagged in the exclusions file. On four-tenths of a millimetre, retinol frequently produces the transient dryness and surface creasing that women over 45 are specifically trying to avoid — 44.6% of cohort members with prior retinol eye experience had stopped using such products for that reason. It also offers nothing immediate: firmness measured at +2%, against up to 27% for our test winner.
A sound choice for a patient user with resilient skin. Not the choice for someone who wants visible contour tightening from the first week without irritation.
Measured results in this evaluation:
- Immediate firmness +2% within minutes, versus up to 27% for our test winner
- Crow’s-feet depth −7.4% at week eight, versus up to 13.8% for our test winner
- Tolerance: best of the retinoid products tested, though 9.2% of its users reported transient dryness
- Fine surface texture: visibly improved from week six
INGREDIENT ANALYSIS::
- Retinol, stabilised and encapsulated — documented action on fine lines over months
- Caffeine — decongestant support
- Glycerin and shea butter — barrier support during the retinisation period
- No fragrance — credited under the committee’s exclusions
A well-made, well-priced retinol option whose mechanism is exactly the one the committee advises caution with on periorbital skin.
4. Clarins – Total Eye Lift
PROS:
- The best-performing conventional “lifting” cream in the test, with a genuine cosmetic tightening sensation
- Pleasant, well-engineered texture and a distinctive applicator
- Good measured improvement in eyelid smoothness
- Long-established brand with substantial internal testing
CONS:
- Its tightening comes from film-forming polymers rather than a glycopeptide fraction: immediate firmness +11%, versus up to 27% for our test winner (criterion 1 not met)
- Fragranced, with a higher rate of subjective stinging recorded than in fragrance-free products (criterion 3 not met)
- Crow’s-feet depth reduced by 5.8% at week eight, versus up to 13.8% for our test winner
- Around £62 for 15ml at UK retail, with no signalling peptide complex at documented dose
OUR VERDICT: Score 86.2 out of 100. Clarins understands the psychology of the eye contour better than almost anyone, and this product delivers a satisfying immediate sensation of tightness that volunteers consistently enjoyed. It was the strongest of the traditional lifting creams and the applicator is genuinely well designed.
But the instrumentation distinguishes between a polymer that dries taut and a glycopeptide mesh that holds tissue under tension. Immediate firmness measured +11% — respectable, and well ahead of the hydrators — but against up to 27% for our test winner. Structurally, the eight-week data were modest: crow’s-feet depth −5.8%, versus up to 13.8% for our test winner.
An enjoyable cosmetic lift. Not, on these measurements, a structural one.
Measured results in this evaluation:
- Immediate firmness +11% within minutes, versus up to 27% for our test winner
- Crow’s-feet depth −5.8% at week eight, versus up to 13.8% for our test winner
- Eyelid smoothness: third highest in the test
- Subjective stinging reported by 7.8% of its users
INGREDIENT ANALYSIS::
- Film-forming polymers — immediate taut sensation, cosmetic rather than structural
- Organic harungana extract — antioxidant support
- Plant-derived hydrating complex — surface moisture
- Fragrance — present; deduction under the periorbital exclusions
A skilfully made cream whose lift you can feel but which the instruments recorded as largely superficial.
5. The Ordinary – Multi-Peptide Eye Serum
PROS:
- Remarkable value, and the most transparent ingredient disclosure of any product in the test
- Fragrance-free, lightweight and fast-absorbing — well suited to thin periorbital skin
- Contains a credible multi-peptide blend, including Matrixyl 3000™
- Recorded no tolerance withdrawals in the cohort
CONS:
- No film-forming glycopeptide at all: immediate firmness +3%, versus up to 27% for our test winner (criterion 1 not met)
- Peptide complex present but assessed by the audit at below the 3% study-level dose, placing it in the under-dosed 82% (criterion 2 not fully met)
- Crow’s-feet depth reduced by 4.9% at week eight, versus up to 13.8% for our test winner
- Around £16 for 15ml at UK retail, and no extended money-back guarantee on opened product
OUR VERDICT: Score 85.4 out of 100, and the committee wishes to be clear that its inclusion is earned. This is an honest, transparent, fragrance-free serum with a sensible texture, sold at a fraction of the price of everything above it. Its inclusion in the top five out of 197 products is a real achievement.
Its limits are the limits of its price. There is no glycopeptide film, so nothing happens on contact — immediate firmness +3%, against up to 27% for our test winner. And while Matrixyl 3000™ is present, the audit placed it below the roughly 3% at which the published 45% wrinkle-density data were generated. Eight-week contour change was accordingly the smallest of the five: −4.9%, versus up to 13.8% for our test winner.
Excellent value. Not, on these measurements, a treatment for an established eye contour at 45-plus.
Measured results in this evaluation:
- Immediate firmness +3% within minutes, versus up to 27% for our test winner
- Crow’s-feet depth −4.9% at week eight, versus up to 13.8% for our test winner
- Hydration +21% at week eight
- Tolerance: no withdrawals recorded
INGREDIENT ANALYSIS::
- Matrixyl 3000™ — present, assessed below the 3% study-level dose
- Additional peptide blend — plausible but not independently quantified
- Hyaluronic acid — surface hydration
- Fragrance-free base — credited under the exclusions
The most honest low-cost serum in the category, held back by dose rather than by intent.
Application Protocol For Comparable Results
The instrumental results reported here were produced under a specific protocol, and the committee recommends readers follow it to obtain comparable outcomes.
Apply a small quantity twice daily, morning and evening, to the orbital bone and the area just beneath it — never to the lash line itself. Tap gently with a fingertip or the supplied applicator rather than rubbing; dragging thin skin is counterproductive.
Allow at least one minute to dry before applying make-up, and apply the serum before any moisturiser so a film-forming active reaches bare skin.
Patch test behind the ear before first use, even with a hypoallergenic formula.
Assess at week four, not week one. The immediate tightening noticed on day one is the film. The contour change is the eight-week story, and the cohort data suggest most women notice it between two and four weeks.
Sun protection should continue regardless. Around 80% of visible facial ageing is attributed to UV exposure rather than the passage of time, and collagen-degrading enzymes activate after as little as 10 to 15 minutes of unprotected exposure — including on cloudy days, since roughly 80% of UV passes through cloud. No eye serum can outrun a bare face in August.
The Committee’s Closing Statement
197 products. 12 evaluation points. 500 women aged 40 and over, across multiple UK sites, over eight weeks. Five products above 85.
The finding that mattered most was not about any single brand. It was that 82% of the audited products contained their headline active below the concentration used in the study the brand itself cited — and that the category’s instinct to make eye products rich is measurably counterproductive on tissue four-tenths of a millimetre thick.
One product satisfied all three criteria: a film-forming glycopeptide above the 2% threshold, a signalling peptide complex at documented dose, and a featherweight fragrance-free base.
“We did not set out to endorse anything,” says Professor Charlotte Weber, MD, Chair of Dermatology. “We set out to measure. On these measurements, one formulation did something the other 196 either could not do or did not do at sufficient dose. Readers should draw their own conclusions, and they should use the guarantee if it does not work for them.”
Results vary between individuals, and none of the products assessed is a substitute for medical or surgical treatment where that is appropriate.
Sources and references
1. ISO 24444 — principles of standardised in-vivo cosmetic assessment (instrumental protocol reference)
2. Nobel Prize in Physiology or Medicine 2009 — telomere and telomerase research on cellular replicative capacity (background science)
3. Double-blind, placebo-controlled clinical study of a Cucurbitaceae-derived active, 44 women aged 60–75, 56 days: hydration +67%, dermal density +56%, deep wrinkle appearance −18.5%
4. Clinical evaluation of palmitoyl tripeptide-1 / palmitoyl tetrapeptide-7 complex: wrinkle density −45%, skin firmness +20% after 2 months
5. Supplier clinical evaluation of standardised Lycium barbarum glycopeptide fraction: skin firmness and elasticity +27% within minutes of application
6. British Skincare Review perception survey, 1,200 UK women aged 45–65, 2024
7. British Skincare Review independent laboratory evaluation: 197 eye treatments, Phase 1 INCI and claims audit; Phase 2 clinical assessment on 500 women aged 40+, 8 weeks, multiple UK sites
This article reports the findings of an independent laboratory and clinical evaluation commissioned by British Skincare Review. All products were purchased anonymously at full retail price and no manufacturer was informed, consulted or given advance sight of the results.
Cosmetic products are not medicines. Nothing in this report is intended to diagnose, treat or cure any condition. Results may vary between individuals, and a patch test is advised before first use.
Competitor prices are indicative UK retail prices at the time of purchase and may change. British Skincare Review may receive a commission on some links, which does not influence scoring or ranking.